Success of the German Cystic Fibrosis Registry.

Pharmacoepidemiol Drug Saf

Mukoviszidose Institut gGmbH, Bonn, Germany.

Published: January 2025

The German Cystic Fibrosis (CF) Registry (GCFR) is a national General Data Protection Regulation-compliant centralised database sponsored by the German Cystic Fibrosis Association (Mukoviszidose e.V.) and based on informed consent for each participating patient, ethical approval, and data protection votes. The aims of the GCFR are to optimise quality of care for CF at the centres, generate epidemiologic overviews, address research questions related to improved CF care, and inform caregivers, patients (aimed at patient empowerment), and health authorities and industry (aimed at care planning and pharmacovigilance). Established in 1995, the Registry has captured data on > 9600 individuals with a combined total of more than 140 000 annual assessments with an estimated coverage rate of > 90%. Patient data are collected after informed consent and confirmed diagnosis of CF, or a CFTR-related disorder, or a screening-positive inconclusive diagnosis of CF (i.e., CFSPID). The registry collects core, encounter, and annual health data. Data include demographics, anthropometrics, lung function, microbiology, CF-specific complications and chronic medications, hospitalisations, demand-oriented antibiotic therapies, and outcomes (death and transplants). Real world and pharmacovigilance studies have been published and additional research underway; there is a formal process for requesting access to the GCFR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706667PMC
http://dx.doi.org/10.1002/pds.70076DOI Listing

Publication Analysis

Top Keywords

german cystic
12
cystic fibrosis
12
fibrosis registry
8
data protection
8
informed consent
8
data
6
success german
4
registry
4
registry german
4
registry gcfr
4

Similar Publications

Perinatal dysfunction of innate immunity in cystic fibrosis.

Sci Transl Med

January 2025

First Department of Medicine, Cardiology, TUM University Hospital, Technical University of Munich, School of Medicine and Health, Munich 81675, Germany.

In patients with cystic fibrosis (CF), repeated cycles of infection and inflammation eventually lead to fatal lung damage. Although diminished mucus clearance can be restored by highly effective CFTR modulator therapy, inflammation and infection often persist. To elucidate the role of the innate immune system in CF etiology, we investigated a CF pig model and compared these results with those for preschool children with CF.

View Article and Find Full Text PDF

[How to identify cystic lateral neck mass from CUP-like lesions: a diagnostic challenge].

Laryngorhinootologie

January 2025

Klinik für Hals-, Nasen- und Ohrenheilkunde, Kopf- Halschirurgie, Universität Heidelberg, Heidelberg, Germany.

A cystic lateral neck mass in adults represents a major challenge, as it can be difficult to distinguish between benign and malignant lesions. The incidence of carcinoma in initially benign treated neck cysts is estimated to be as high as 24%. The objective of this study was to ascertain the malignancy rate of cystic cervical masses and to provide a differentiation of cervical metastases in comparison to benign cervical cysts, utilising current guidelines.

View Article and Find Full Text PDF

Success of the German Cystic Fibrosis Registry.

Pharmacoepidemiol Drug Saf

January 2025

Mukoviszidose Institut gGmbH, Bonn, Germany.

The German Cystic Fibrosis (CF) Registry (GCFR) is a national General Data Protection Regulation-compliant centralised database sponsored by the German Cystic Fibrosis Association (Mukoviszidose e.V.) and based on informed consent for each participating patient, ethical approval, and data protection votes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!